These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application. Bramhall SR Int J Pancreatol; 1997 Feb; 21(1):1-12. PubMed ID: 9127168 [TBL] [Abstract][Full Text] [Related]
43. Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. Denhardt DT; Feng B; Edwards DR; Cocuzzi ET; Malyankar UM Pharmacol Ther; 1993 Sep; 59(3):329-41. PubMed ID: 8309995 [TBL] [Abstract][Full Text] [Related]
44. Role and regulation of metalloproteinases in connective tissue turnover. Murphy G; Hembry RM; Hughes CE; Fosang AJ; Hardingham TE Biochem Soc Trans; 1990 Oct; 18(5):812-5. PubMed ID: 2083684 [No Abstract] [Full Text] [Related]
45. Metalloproteinase inhibitors and the prevention of connective tissue breakdown. Cawston TE Pharmacol Ther; 1996; 70(3):163-82. PubMed ID: 8888065 [TBL] [Abstract][Full Text] [Related]
46. Role of type IV collagenases in human breast cancer. Stetler-Stevenson WG; Liotta LA; Brown PD Cancer Treat Res; 1992; 61():21-41. PubMed ID: 1360233 [No Abstract] [Full Text] [Related]
47. Nomenclature and glossary of the matrix metalloproteinases. Nagase H; Barrett AJ; Woessner JF Matrix Suppl; 1992; 1():421-4. PubMed ID: 1480083 [No Abstract] [Full Text] [Related]
48. Regulation of matrix metalloproteinases during extracellular matrix turnover. Corcoran ML; Kleiner DE; Stetler-Stevenson WG Adv Exp Med Biol; 1995; 385():151-9; discussion 179-84. PubMed ID: 8571826 [No Abstract] [Full Text] [Related]
50. Plasma assay of matrix metalloproteinases (MMPs) and MMP-inhibitor complexes in cancer. Potential use in predicting metastasis and monitoring treatment. Zucker S; Lysik RM; Zarrabi HM; Moll U; Tickle SP; Stetler-Stevenson W; Baker TS; Docherty AJ Ann N Y Acad Sci; 1994 Sep; 732():248-62. PubMed ID: 7978797 [No Abstract] [Full Text] [Related]
51. The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases. Docherty AJ; O'Connell J; Crabbe T; Angal S; Murphy G Trends Biotechnol; 1992 Jun; 10(6):200-7. PubMed ID: 1368394 [TBL] [Abstract][Full Text] [Related]
52. Tissue inhibitors of metalloproteinases and their cell growth-promoting activity. Hayakawa T Cell Struct Funct; 1994 Jun; 19(3):109-14. PubMed ID: 7954870 [No Abstract] [Full Text] [Related]
53. The molecular and cellular interactions involved in connective tissue destruction. Reynolds JJ Br J Dermatol; 1985 Jun; 112(6):715-23. PubMed ID: 3890925 [No Abstract] [Full Text] [Related]
54. Targeted disruption of the tissue inhibitor of metalloproteinases gene increases the invasive behavior of primitive mesenchymal cells derived from embryonic stem cells in vitro. Alexander CM; Werb Z J Cell Biol; 1992 Aug; 118(3):727-39. PubMed ID: 1639854 [TBL] [Abstract][Full Text] [Related]
55. Design and synthetic considerations of matrix metalloproteinase inhibitors. Skotnicki JS; Zask A; Nelson FC; Albright JD; Levin JI Ann N Y Acad Sci; 1999 Jun; 878():61-72. PubMed ID: 10415720 [TBL] [Abstract][Full Text] [Related]
56. Structure-function studies of mouse tissue inhibitor of metalloproteinases-1. Denhardt DT; Rajan S; Walther SE Ann N Y Acad Sci; 1994 Sep; 732():65-74. PubMed ID: 7978852 [No Abstract] [Full Text] [Related]
57. Metalloproteinases: role in pathology and development of inhibitors. 6th British Inflammation Research Association Meeting, 4 April 1990, University of Bath. Henderson B; Hall ND Agents Actions; 1991 Nov; 34(3-4):324-8. PubMed ID: 1810145 [No Abstract] [Full Text] [Related]
58. Blocking cartilage destruction with metalloproteinase inhibitors: a valid therapeutic target? Cawston T Ann Rheum Dis; 1993 Nov; 52(11):769-70. PubMed ID: 8250606 [No Abstract] [Full Text] [Related]